More recently, the formulation of a defined polyprotein anti-Leishmania vaccine candidate in conjunction with TLR4 or TLR9 agonists was evaluated as an immunotherapeutical treatment in a mouse model of cutaneous leishmaniasis [95]. This evidence concerns the gene TLR4 and cutaneous leishmaniasis.